CClinicalTrials.gg
RecruitingNCT02267252Updated Nov 2, 2023

Effects of Male-specific Antibodies on Sex Ratio

An observational study in Sperm Antibodies and Sex Ratio, sponsored by Odense University Hospital. Recruiting at 1 site in Denmark. Open to male participants aged 25 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-02.

Sponsored by Odense University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2014; still recruiting 12 years 1 month later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
30
Ages
25 Years and older
Sex
Male
01

Study summary

Investigation of the ability of antibodies from vasectomized men in binding to Y-spermatozoa as a possible explanation of the lower sex ratio observed after microinsemination using epididymal sperm from vasectomized men.

02

Conditions studied

  • Sperm Antibodies
  • Sex Ratio
03

In context

Lead sponsor

Odense University Hospital is the lead sponsor of 468 studies on the registry; 109 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Vasectomized men

Inclusion criteria

  • Vasectomized men

Exclusion criteria

Exclusion Criteria:

  • Men who do not understand the study information
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherAntibody-sperm binding
06

What researchers measure

Primary outcomes

  1. Y/X sperm ratio after exposure to sperm-specific antibodies

    Time frame: Up to 28 months

07

Study locations

1 of 1 sites recruiting
  • Fertility Clinic, Odense University Hospital
    Odense, 5000, Denmark
    • Jens Fedder, Professor · Contact · fedder@dadlnet.dk · +45 268 20 368
    • Jens Fedder, Professor · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02267252
Lead sponsor
Odense University Hospital
Responsible party
Jens Fedder (Professor, Consultant, Ph.D., Odense University Hospital) — Principal investigator
First posted
Oct 17, 2014
Start date
Sep 2014
Primary completion
Dec 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
Nov 2, 2023

Study contacts

Jens Fedder, MD, PhD
Contact
fedder@dadlnet.dk
+45 26820368

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion